Entering text into the input field will update the search result below

Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential

George Crist profile picture
George Crist


  • Context Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications.
  • Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of September of 2021.
  • Context Therapeutics debuted last week at a far lower price than originally contemplated, while the sector (XBI) was almost 40% down from its February high.
  • In my opinion, this company is undervalued and an opportunity exists to take a position before the larger market realizes the potential within Context's pipeline.


theasis/E+ via Getty Images

What a year it has been for biotech investors

The world has profoundly changed since COVID-19 arrived. Loved ones departed too early. Economies and supply chains wrecked. Early cancer diagnoses missed because of lack of access to care. I'm

This article was written by

George Crist profile picture
Follow me as well at Twitter @crist_phd. I manage the holdings of a small progressively structured alternative biotechnology hedge fund and I have been investing nearly exclusively in biotech for 20 years. My clinical focus is on oncology and unmet medical needs. I'm published in the field of metabolism and hold a US Patent for a novel therapy for NIDDM which unfortunately died on a shelf at big Pharma. My children describe me as a doctor who doesn't help anybody...truth hurts.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CNTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.